Ministry of Food and Drug Safety 국민 안심이 기준입니다 YOUR SAFETY IS OUR STANDARD

Ministry of Food and Drug Safety 국민 안심이 기준입니다 YOUR SAFETY IS OUR STANDARD

home > Our Works > Bio&Cosmetics > Manufactures
Manufactures|Bio&Cosmetics|Our Works|Ministry of Food and Drug Safety

Biological Products

(Biologics, Recombinant DNA products) Daewoong Pharmaceutical Co.,Ltd
  • Registration Date 2016-07-11
  • Hit 6229

Company Information

1. Name

Daewoong Pharmaceutical Co., Ltd

2. Website Address

http://www.daewoong.com/

3. Location

Bongeunsaro114-gil 12, Kangnam-gu, Seoul, Republic of Korea

4. Contacts

Biologics : +82-2-2190-6851

non-biologic : +82-2-2190-6861

5. References

Pharmaceutical Product Information

1.Brand Name

Easyef soln 0.005%

2.Active Ingredient

Recombinant human epidermal growth factor (EGF) - 1mg/20ml

3.Indication

Diabetic foot ulcer, Indication to be extened(cosmetic peeling surgery,skin burn,corneal ulcer)

4.Information

Epidermal growth factors to induce skin cell and keratocyte regeneration.

Effective in curing keratohelcosis, corneal disorders, wounds, diabetic ulcer, bedsore, etc

5.Images

Pharmaceutical Product Information

1.Brand Name

Caretropin

2.Active Ingredient

Somatropin ( 5.3mg (16IU))

3.Indication

Growth Hormone Deficiency in adult

4.Information

Dosage & Administration

Adult Growth Hormone Deficiency (GHD) The recommended dosage at the start of therapy is 0.125IU (0.04mg) /kg/week given as a daily subcutaneous injection (6~7 divided dose). The dose may be increased gradually according to individual patient requirements to a maximum of 0.25IU (0.08mg)/kg/week. Clinical response, side effects, and determination of age-and gender-adjusted serum insulin-like growth factor(IGF-1) levels may be used as guidance in dose titration. Minimum effective dose should be used. The dosage of somatropin should be decreased in cases of persistent edema or severe paresthesia, in order to avoid the development of carpal tunnel syndrome

5.Images

Pharmaceutical Product Information

Brand Name

NABOTA inj.

Active Ingredient

Clostridium Botulinum Toxin Type A

Indication

Temporary improvement of glabellar wrinkles

Information

Nabota, originated from wild-type Clostridium botulinum, is produced by the guideline of WHO GMP. Nabota was approved by Korean FDA in 2013, launched in 2014 and contracted for export into 90 countries.

Images


Attached File

Division

Written by 전형옥